These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

813 related articles for article (PubMed ID: 21262219)

  • 1. (2S,4S)-4-Fluoro-1-{[(2-hydroxy-1,1-dimethylethyl)amino]acetyl}-pyrrolidine-2-carbonitrile monobenzenesulfonate (TS-021) is a selective and reversible dipeptidyl peptidase IV inhibitor.
    Tajima A; Yamamoto K; Kozakai A; Okumura-Kitajima L; Mita Y; Kitano K; Jingu S; Nakaike S
    Eur J Pharmacol; 2011 Mar; 655(1-3):99-107. PubMed ID: 21262219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RBx-0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase-IV for the treatment of type 2 diabetes.
    Singh S; Roy S; Sethi S; Benjamin B; Sundaram S; Khanna V; Kandalkar SR; Pal C; Kant R; Patra AK; Rayasam G; Mittra S; Saini KS; Paliwal J; Chugh A; Ahmed S; Sattigeri J; Cliff I; Ray A; Bansal VS; Bhatnagar PK; Davis JA
    Eur J Pharmacol; 2011 Feb; 652(1-3):157-63. PubMed ID: 20540938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys.
    Lee B; Shi L; Kassel DB; Asakawa T; Takeuchi K; Christopher RJ
    Eur J Pharmacol; 2008 Jul; 589(1-3):306-14. PubMed ID: 18538760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ASP4,000, a novel, selective, dipeptidyl peptidase 4 inhibitor with antihyperglycemic activity.
    Tanaka-Amino K; Matsumoto K; Hatakeyama Y; Shima I; Takakura S; Muto S
    Eur J Pharmacol; 2008 Aug; 590(1-3):444-9. PubMed ID: 18582861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats.
    Balkan B; Kwasnik L; Miserendino R; Holst JJ; Li X
    Diabetologia; 1999 Nov; 42(11):1324-31. PubMed ID: 10550416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ASP8497 is a novel selective and competitive dipeptidyl peptidase-IV inhibitor with antihyperglycemic activity.
    Matsuyama-Yokono A; Tahara A; Nakano R; Someya Y; Nagase I; Hayakawa M; Shibasaki M
    Biochem Pharmacol; 2008 Jul; 76(1):98-107. PubMed ID: 18468582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 7-But-2-ynyl-9-(6-methoxy-pyridin-3-yl)-6-piperazin-1-yl-7,9-dihydro-purin-8-one is a novel competitive and selective inhibitor of dipeptidyl peptidase IV with an antihyperglycemic activity.
    Yamazaki K; Yasuda N; Inoue T; Nagakura T; Kira K; Shinoda M; Saeki T; Tanaka I
    J Pharmacol Exp Ther; 2006 Dec; 319(3):1253-7. PubMed ID: 16980568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, improves postprandial hyperglycemia and dyslipidemia after single and repeated administrations.
    Fukuda-Tsuru S; Anabuki J; Abe Y; Yoshida K; Ishii S
    Eur J Pharmacol; 2012 Dec; 696(1-3):194-202. PubMed ID: 23022337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel long acting DPP-IV inhibitor PKF-275-055 stimulates β-cell proliferation resulting in improved glucose homeostasis in diabetic rats.
    Akarte AS; Srinivasan BP; Gandhi S
    Biochem Pharmacol; 2012 Jan; 83(2):241-52. PubMed ID: 22015634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological profile of ASP8497, a novel, selective, and competitive dipeptidyl peptidase-IV inhibitor, in vitro and in vivo.
    Someya Y; Tahara A; Nakano R; Matsuyama-Yokono A; Nagase I; Fukunaga Y; Takasu T; Hayakawa M; Shibasaki M
    Naunyn Schmiedebergs Arch Pharmacol; 2008 May; 377(3):209-17. PubMed ID: 18398600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological profiles of gemigliptin (LC15-0444), a novel dipeptidyl peptidase-4 inhibitor, in vitro and in vivo.
    Kim SH; Jung E; Yoon MK; Kwon OH; Hwang DM; Kim DW; Kim J; Lee SM; Yim HJ
    Eur J Pharmacol; 2016 Oct; 788():54-64. PubMed ID: 27298192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of dipeptidyl-peptidase IV catalyzed peptide truncation by Vildagliptin ((2S)-{[(3-hydroxyadamantan-1-yl)amino]acetyl}-pyrrolidine-2-carbonitrile).
    Brandt I; Joossens J; Chen X; Maes MB; Scharpé S; De Meester I; Lambeir AM
    Biochem Pharmacol; 2005 Jul; 70(1):134-43. PubMed ID: 15907807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of the dipeptidyl peptidase-IV inhibitor ASP8497 on glucose tolerance in animal models of secondary failure.
    Someya Y; Nakano R; Tahara A; Takasu T; Takeuchi A; Nagase I; Matsuyama-Yokono A; Hayakawa M; Sasamata M; Miyata K; Uchiyama Y
    Eur J Pharmacol; 2009 Nov; 622(1-3):71-7. PubMed ID: 19766107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
    Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
    Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and biological evaluation of pyrrolidine-2-carbonitrile and 4-fluoropyrrolidine-2-carbonitrile derivatives as dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes.
    Wang J; Feng Y; Ji X; Deng G; Leng Y; Liu H
    Bioorg Med Chem; 2013 Dec; 21(23):7418-29. PubMed ID: 24153396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. (2S,4S)-1-[2-(1,1-dimethyl-3-oxo-3-pyrrolidin-1-yl-propylamino)acetyl]-4-fluoro-pyrrolidine-2-carbonitrile: a potent, selective, and orally bioavailable dipeptide-derived inhibitor of dipeptidyl peptidase IV.
    Yeh TK; Tsai TY; Hsu T; Cheng JH; Chen X; Song JS; Shy HS; Chiou MC; Chien CH; Tseng YJ; Huang CY; Yeh KC; Huang YL; Huang CH; Huang YW; Wang MH; Tang HK; Chao YS; Chen CT; Jiaang WT
    Bioorg Med Chem Lett; 2010 Jun; 20(12):3596-600. PubMed ID: 20483603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DPP-4 inhibition increases GIP and decreases GLP-1 incretin effects during intravenous glucose tolerance test in Wistar rats.
    Freyse EJ; Berg S; Kohnert KD; Heinke P; Salzsieder E
    Biol Chem; 2011 Mar; 392(3):209-15. PubMed ID: 21281062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the pharmacokinetics, food effect, pharmacodynamics, and tolerability of DA-1229, a dipeptidyl peptidase IV inhibitor, in healthy volunteers: first-in-human study.
    Kim TE; Lim KS; Park MK; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
    Clin Ther; 2012 Sep; 34(9):1986-98. PubMed ID: 22943970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. K579, a slow-binding inhibitor of dipeptidyl peptidase IV, is a long-acting hypoglycemic agent.
    Takasaki K; Iwase M; Nakajima T; Ueno K; Nomoto Y; Nakanishi S; Higo K
    Eur J Pharmacol; 2004 Feb; 486(3):335-42. PubMed ID: 14985056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antihyperglycemic effects of ASP8497 in streptozotocin-nicotinamide induced diabetic rats: comparison with other dipeptidyl peptidase-IV inhibitors.
    Tahara A; Matsuyama-Yokono A; Nakano R; Someya Y; Hayakawa M; Shibasaki M
    Pharmacol Rep; 2009; 61(5):899-908. PubMed ID: 19904014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.